News

March 2018

Physical Pharmaceutica announces its proprietary, first-of-its-kind screening polymers and excipients for supersaturating formulation precipitation (spring and parachute screening). 

September 2016

Physical Pharmaceutica awarded contract from the U.S. Food and Drug Administration to study release from cyclosporine ophthalmic emulsions ("Pulsatile microdialysis for in vitro release of ophthalmic emulsions")

September 2016

Meet us in Denver at the AAPS 2016 Annual Meeting. (Posters 21M0130, 21T1230, 21W0330)

July 2016

We have moved and expanded!  Our new address is 30 Ramland Road, Suite 105, Orangeburg, NY 10962

October 2015 
Meet us in Orlando at the AAPS 2015 Annual Meeting.  (Posters M1294 and M1319)

September 2014

Physical Pharmaceutica awarded grant from U.S. Food and Drug Administration to study food drug interactions ("Predictive in vitro Methods Characterizing Product Performance, Case Study: Furosemide”)

March 2014

Physical Pharmaceutica awarded fifth PMD patent (Patent 8,679,052)

February 2014

Physical Pharmaceutica awarded three more PMD patents. (Patents 8,647,295; 8,652,087; 8,652,088)

December 2012

Physical Pharmaceutica awarded first pulsatile microdialysis (PMD) patent. (Patent 8,333,107)

September 2012

Physical Pharmaceutica awarded contract from U.S. Food and Drug Administration to study dissolution from nanoparticle formulations ("Investigation of Nano-particle Formulations")​